PedAM
Pediatric Disease Annotations & Medicines
| Disease | breast cancer |
| Phenotype | C0029456|osteoporosis |
| Sentences | 8 |
| PubMedID- 24614816 | Of note, these drugs are mainly developed for osteoporosis treatment with breast cancer treatment as a secondary endpoint [6], which makes it in urgent need to develop novel er-α modulators. |
| PubMedID- 23017944 | The management of osteoporosis in breast cancer survivors. |
| PubMedID- 26334646 | The effectiveness of bisphosphonates has been demonstrated in various large-scale clinical studies and denosumab has been shown to be at least as effective in breast cancer patients with aromatase inhibitor-induced osteoporosis and in men with prostate cancer under hormone ablation therapy. |
| PubMedID- 20160722 | Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. |
| PubMedID- 26298334 | Conclusions: zoledronic acid appears to prevent further bone loss in postmenopausal breast cancer patients with osteopenia and osteoporosis starting treatment with letrozole. |
| PubMedID- 20079640 | Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. |
| PubMedID- 20374022 | Background: osteoporosis is of concern in breast cancer patients who are undergoing chemotherapy. |
| PubMedID- 21898151 | In summary, here, we report the prevalence of non-cancer endpoints in a cohort of b1/2 mutation carriers and note a particularly high rate of osteopenia and osteoporosis in b1/2 with breast cancer undergoing rrso prior to 50. |
Page: 1